OpenNashPodcasts

Person

Stephane Bancel

This page collects what Stephane Bancel, CEO of Moderna, has said on podcasts including In Good Company with Nicolai Tangen, The Long Run with Luke Timmerman and Raising Health from a16z. They cover Moderna's mRNA technology, its COVID-19 vaccine work, his earlier career, and its personalized cancer treatment.

Bancel told Nicolai Tangen that Moderna made COVID-19 its top priority after he realised at Davos in January 2020 that the virus would become a pandemic. He told Luke Timmerman that Moderna began full operations in the summer of 2011. On Raising Health, he said Moderna and Merck hope to offer the melanoma treatment in 2027.

3 episodes · 68 quoted claims

Stephane Bancel says he first learned of a new pneumonia-like disease in Wuhan, China from a Wall Street Journal article read on holiday in the south of France just after Christmas 2019.

“And there was a Wall Street Journal article that I read when I was actually in the south of France on vacation just a few days after Christmas 2019”

In Good Company with Nicolai Tangen · 0:00:37

Bancel says Moderna waited for January 10, when Chinese researchers posted the new coronavirus's genetic sequence online.

“So we waited for January 10, when the Chinese put this genetic sequence online.”

In Good Company with Nicolai Tangen · 0:01:20

Bancel says he realised at Davos in the week of January 20, 2020 that the virus would be a pandemic like 1918, and he then made COVID-19 Moderna's top priority.

“It's only when I'm in Davos the week of January 20 that I realized that this was going to be a pandemic like 1918.”

In Good Company with Nicolai Tangen · 0:01:45

Bancel says Moderna had worked on its mRNA technology for about 10 years and had put nine vaccines into human testing before COVID-19 appeared.

“we have this technology that we've been working on for 10 years we've done 9 vaccines in human testing when COVID-19 appears”

In Good Company with Nicolai Tangen · 0:02:17

Bancel says Moderna designs its vaccines on a computer from genetic data and then sends the instructions to robots that make the vaccine.

“We use genetic information, so just data, to design the vaccine on the computer. And then the instructions go to robots, and the robots start making the vaccine.”

In Good Company with Nicolai Tangen · 0:03:57

Bancel says Moderna's manufacturing process is the same for every mRNA vaccine, and the only difference between flu, COVID and Zika vaccines is the order of the genetic letters.

“Because the only difference with flu vaccine and COVID vaccine and Zika vaccine is only the orders of the letters on the message.”

In Good Company with Nicolai Tangen · 0:03:57

Bancel says Moderna's team began working seven days a week around February 2020 and kept that up for nine months.

“We started around February of 2020 to actually work seven days a week which was dreadful because it was not a few weekends it was for nine months”

In Good Company with Nicolai Tangen · 0:04:27

Bancel says Moderna shut down some trial sites that were enrolling only white people and opened a new site to recruit more African-Americans.

“We actually shut down a few of the clinical trial sites where they were enrolling only white people and focusing energy and opening a new site to do more recruiting of African-Americans.”

In Good Company with Nicolai Tangen · 0:06:55

Bancel says Moderna was among the first companies in Massachusetts to set up its own testing lab, in spring 2020, so candidates could be tested for onsite interviews.

“We set up our own lab, which we were one of the first companies in Massachusetts to set up our own lab back in the spring of 2020.”

In Good Company with Nicolai Tangen · 0:08:49

Bancel says he publicly appealed on TV and radio for Moderna to hire 500 people in Cambridge or Norwood, Massachusetts, where its plant was.

“I will be sometime on TV or on radio saying, hey, we need to hire 500 people in Cambridge or in Norwood where our plant was.”

In Good Company with Nicolai Tangen · 0:10:31

Bancel says Moderna's Massachusetts plant made $600 million in 2021 and runs entirely without paper.

“If you look at our plant in Massachusetts that has made $600 million last year in 2021, there is no paper in that plant.”

In Good Company with Nicolai Tangen · 0:11:18

Bancel says Moderna chose a 100-microgram dose for its COVID-19 vaccine, which he believes gave longer protection than other vaccines.

“So we ended up picking 100 micrograms, which ended up giving the Mona vaccine a much longer duration of protection than the other vaccines.”

In Good Company with Nicolai Tangen · 0:13:54

Bancel says he was raised by the Jesuits, which gave him a serving mindset that shaped his career in life science.

“I was raised by the Jesuits so kind of a serving mindset I've been in life science all my life”

In Good Company with Nicolai Tangen · 0:02:17

Bancel previously ran BioMérieux, a French diagnostics company built by the Mérieux family.

“I used to run BioMérieux. It's a French-based diagnostic company. It was built by a family, the family of Marieux.”

In Good Company with Nicolai Tangen · 0:17:46

Bancel says Moderna gave a drug for a rare genetic disease to a foundation in the fall before this interview.

“we recently, in the fall, we gave away a drug for rare genetic disease to a foundation.”

In Good Company with Nicolai Tangen · 0:18:42

Bancel says that for the rare disease Crigler-Najjar, Moderna would have had to charge about $1 million per child per year just to cover its clinical costs.

“we realized that because the number of kids is so small, if we just want to break even our clinical costs, we will have to charge a family around $1 million per year per kid.”

In Good Company with Nicolai Tangen · 0:19:17

Bancel says Moderna committed by contract to supply the approved drug free every year to the couple of hundred affected children worldwide.

“And we committed by contract that if the drug is approved, we will every year supply to those couple hundred kids in the planet.”

In Good Company with Nicolai Tangen · 0:20:41

Bancel says Moderna's vision is a once-a-year booster combining COVID, flu, RSV and other coronavirus protection.

“So our vision is to save millions of lives every year by providing a once a year booster that has COVID in it”

In Good Company with Nicolai Tangen · 0:23:40

Bancel says China shows little appetite for foreign vaccines, which he sees as a problem for its zero-COVID policy.

“There's not a lot of appetite today to get foreign vaccine used in China.”

In Good Company with Nicolai Tangen · 0:25:56

Stéphane Bancel says Moderna put six new drugs into clinical trials in 2017, bringing its total to 10 in the clinic.

“We put six new drugs in clinical trial. So today we have 10 drugs in clinical trial, which is a great number”

The Long Run with Luke Timmerman · 0:05:17

Bancel says Moderna's first successful phase one therapeutic trial was a VEGF program for the heart run with AstraZeneca, meeting its primary and secondary endpoints.

“We had our first phase one for therapeutics that was successful with AstraZeneca for VEGF in the heart, met primary, secondary endpoint.”

The Long Run with Luke Timmerman · 0:05:50

After a master's in biochemical engineering at Minnesota, Stéphane Bancel moved to Tokyo and lived there for almost four years working for bioMérieux.

“And so I went from Minnesota straight to Tokyo. And I lived in Tokyo for almost four years.”

The Long Run with Luke Timmerman · 0:10:18

Stéphane Bancel graduated from Harvard Business School in May 2000, when the Nasdaq peaked, and then joined Eli Lilly instead of a dot-com company.

“I graduated in May 2000 which as you know is when the Nasdaq peaked”

The Long Run with Luke Timmerman · 0:13:29

Bancel says an FDA warning letter on Eli Lilly's injectable insulin manufacturing site held up Lilly's planned biologic launches, because those products were to be made in the same plant.

“because there was a warning letter on the injectable site that was making insulin, all the biologics needed to be injected as well.”

The Long Run with Luke Timmerman · 0:18:06

As Eli Lilly's country manager for Belgium, Stéphane Bancel helped launch Alimta, Cymbalta and Cialis.

“we launched new products like Alimta for cancer, Cymbalta for CNS. We launched Cialis which was a really fun product to launch”

The Long Run with Luke Timmerman · 0:19:53

Stéphane Bancel was 32 when Alain Mérieux first raised the idea of him becoming CEO of bioMérieux.

“of course you are way too young to have a chance I was 32 at the time to have a chance”

The Long Run with Luke Timmerman · 0:20:47

Bancel says bioMérieux operated in 42 countries, with about 10 plants and 10 or 11 labs, while he was CEO.

“We had presence in 42 countries. So we had teams in 42 countries. I think 10 plants around the world, 10 or 11 labs around the world.”

The Long Run with Luke Timmerman · 0:24:03

The experiment Nubar Afeyan showed Bancel, from a Harvard lab, involved injecting mRNA encoding a human protein into mouse muscle and finding the human protein in the mouse's blood.

“showing that they had injected, you know, mRNA-encoded human hippo in a mouse muscle.”

The Long Run with Luke Timmerman · 0:28:13

Bancel says about two-thirds of human proteins act inside cells and only about a third enter the bloodstream, which was the part biotech drugs had mainly reached.

“around two-thirds of a human protein, a proteome, are intracellular protein. It's only a third that goes into the bloodstream”

The Long Run with Luke Timmerman · 0:30:27

Bancel had Moderna test two drugs in monkeys at once so that investors and pharma partners could not dismiss a single success as luck.

“we tried two drugs in Monkey at the same time because I told myself if we do only one, everybody is going to tell me”

The Long Run with Luke Timmerman · 0:37:18

Bancel set Moderna's early team a goal of making 100 different proteins in mice, a number he says he picked arbitrarily.

“I asked them to do 100 different proteins in mice.”

The Long Run with Luke Timmerman · 0:37:56

Bancel says he first met AstraZeneca CEO Pascal Soriot at a three-hour breakfast in December 2012 during the partnership talks.

“he set up a breakfast in Gettysburg with Pascal in December of 2012. And so I met Pascal for the first time.”

The Long Run with Luke Timmerman · 0:46:16

Bancel says Moderna's first financing rounds before the AstraZeneca deal were $2 million, $2 million, $7 million and $25 million.

“The first round of Moderna, everybody forgets, was $2 million. The A of Moderna was $2 million. The B was $7 million. And the C was $25 million.”

The Long Run with Luke Timmerman · 0:50:36